Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Exciting CAR-T data in multiple myeloma and follicular lymphoma: CARTITUDE-2, ELARA & ZUMA-5

Bhagirathbhai Dholaria • 24 Apr 2022
The 2022 Tandem Meetings
Follicular Lymphoma Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T Ciltacabtagene autoleucel Tisagenlecleucel
CARTITUDE-2 ELARA

Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, shares his thoughts on the most exciting data in CAR-T therapy that has been released at this year’s Tandem Meetings, including results from the CARTITUDE-2 (NCT04133636), ELARA (NCT03568461), and ZUMA-5 (NCT03105336) studies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Bhagirathbhai Dholaria

1:06
Feasibility of treatment with bispecifics in patients with myeloma with prior BCMA exposure
Bhagirathbhai Dholaria • 2 Jun 2023
1:44
TRIMM-2: talquetamab + daratumumab in patients with R/R multiple myeloma
Bhagirathbhai Dholaria • 2 Jun 2023
1:27
Challenges in CAR-T therapy for myeloid malignancies
Bhagirathbhai Dholaria • 24 Apr 2022
2:05
Cord blood transplantation vs MMUD with PTCy in AML
Bhagirathbhai Dholaria • 24 Apr 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals